NightHawk Biosciences Inc
ASE:NHWK
| Market Cap (Intraday) | 13.72M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.59 |
| 50-Day MA | $0.64 |
| 200-Day MA | $0.80 |
NightHawk Biosciences Inc Stock, ASE:NHWK
627 Davis Drive, Suite 300, Morrisville, North Carolina 27560
United States of America
Phone: +1.919.240.7133
Number of Employees: 77
Description
NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.